181 related articles for article (PubMed ID: 24421342)
1. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.
D'Avino C; Paciello R; Riccio G; Coppola C; Laccetti P; Maurea N; Raines RT; De Lorenzo C
Protein Eng Des Sel; 2014 Mar; 27(3):83-8. PubMed ID: 24421342
[TBL] [Abstract][Full Text] [Related]
2. A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.
Riccio G; D'Avino C; Raines RT; De Lorenzo C
Protein Eng Des Sel; 2013 Mar; 26(3):243-8. PubMed ID: 23232187
[TBL] [Abstract][Full Text] [Related]
3. A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.
Borriello M; Laccetti P; Terrazzano G; D'Alessio G; De Lorenzo C
Br J Cancer; 2011 May; 104(11):1716-23. PubMed ID: 21559015
[TBL] [Abstract][Full Text] [Related]
4. Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent.
De Lorenzo C; Di Malta C; Calì G; Troise F; Nitsch L; D'Alessio G
FEBS Lett; 2007 Jan; 581(2):296-300. PubMed ID: 17208233
[TBL] [Abstract][Full Text] [Related]
5. Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.
Gelardi T; Damiano V; Rosa R; Bianco R; Cozzolino R; Tortora G; Laccetti P; D'Alessio G; De Lorenzo C
Br J Cancer; 2010 Feb; 102(3):513-9. PubMed ID: 20051960
[TBL] [Abstract][Full Text] [Related]
6. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor.
Troise F; Cafaro V; Giancola C; D'Alessio G; De Lorenzo C
FEBS J; 2008 Oct; 275(20):4967-79. PubMed ID: 18795950
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.
De Lorenzo C; Troise F; Cafaro V; D'Alessio G
Br J Cancer; 2007 Nov; 97(10):1354-60. PubMed ID: 17923870
[TBL] [Abstract][Full Text] [Related]
8. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
Fedele C; Riccio G; Coppola C; Barbieri A; Monti MG; Arra C; Tocchetti CG; D'Alessio G; Maurea N; De Lorenzo C
Breast Cancer Res Treat; 2012 Jun; 133(2):511-21. PubMed ID: 21947749
[TBL] [Abstract][Full Text] [Related]
9. A novel human antitumor dimeric immunoRNase.
Riccio G; Borriello M; D'Alessio G; De Lorenzo C
J Immunother; 2008 Jun; 31(5):440-5. PubMed ID: 18463541
[TBL] [Abstract][Full Text] [Related]
10. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells.
De Lorenzo C; Nigro A; Piccoli R; D'Alessio G
FEBS Lett; 2002 Apr; 516(1-3):208-12. PubMed ID: 11959134
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents.
Riccio G; Esposito G; Leoncini E; Contu R; Condorelli G; Chiariello M; Laccetti P; Hrelia S; D'Alessio G; De Lorenzo C
FASEB J; 2009 Sep; 23(9):3171-8. PubMed ID: 19417081
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.
Balandin TG; Edelweiss E; Andronova NV; Treshalina EM; Sapozhnikov AM; Deyev SM
Invest New Drugs; 2011 Feb; 29(1):22-32. PubMed ID: 19789841
[TBL] [Abstract][Full Text] [Related]
14. Biological properties of a human compact anti-ErbB2 antibody.
De Lorenzo C; Cozzolino R; Carpentieri A; Pucci P; Laccetti P; D'Alessio G
Carcinogenesis; 2005 Nov; 26(11):1890-5. PubMed ID: 15930029
[TBL] [Abstract][Full Text] [Related]
15. ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction.
Perry MC; Dufour CR; Eichner LJ; Tsang DW; Deblois G; Muller WJ; Giguère V
Mol Cell Biol; 2014 Dec; 34(23):4232-43. PubMed ID: 25246633
[TBL] [Abstract][Full Text] [Related]
16. Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies.
De Lorenzo C; D'Alessio G
FEBS J; 2009 Mar; 276(6):1527-35. PubMed ID: 19220462
[TBL] [Abstract][Full Text] [Related]
17. Effects of a human compact anti-ErbB2 antibody on prostate cancer.
Malara AE; Fedele C; Aloj L; Arra C; Laccetti P; D'Alessio G; De Lorenzo C
Oncol Rep; 2012 Jul; 28(1):297-302. PubMed ID: 22505344
[TBL] [Abstract][Full Text] [Related]
18. Effects of a human compact anti-ErbB2 antibody on gastric cancer.
Fedele C; Carvalho S; Riccio G; Paciello R; Laccetti P; Schmitt F; De Lorenzo C
Gastric Cancer; 2014 Jan; 17(1):107-15. PubMed ID: 23460348
[TBL] [Abstract][Full Text] [Related]
19. A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent.
De Lorenzo C; Tedesco A; Terrazzano G; Cozzolino R; Laccetti P; Piccoli R; D'Alessio G
Br J Cancer; 2004 Sep; 91(6):1200-4. PubMed ID: 15305184
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
